Incyte Co. (NASDAQ:INCY) Shares Acquired by V Square Quantitative Management LLC

V Square Quantitative Management LLC increased its stake in shares of Incyte Co. (NASDAQ:INCY) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,963 shares of the biopharmaceutical company’s stock after purchasing an additional 155 shares during the quarter. V Square Quantitative Management LLC’s holdings in Incyte were worth $262,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in shares of Incyte by 48.8% in the fourth quarter. Wellington Management Group LLP now owns 131,649 shares of the biopharmaceutical company’s stock valued at $8,266,000 after buying an additional 43,160 shares during the last quarter. Nomura Holdings Inc. acquired a new position in Incyte in the 4th quarter valued at $235,000. Mather Group LLC. purchased a new position in shares of Incyte during the 1st quarter worth $54,000. Gateway Investment Advisers LLC acquired a new stake in shares of Incyte during the first quarter worth $205,000. Finally, Riverview Trust Co purchased a new stake in shares of Incyte in the first quarter valued at $29,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Stock Performance

Shares of INCY opened at $66.39 on Monday. Incyte Co. has a 52-week low of $50.27 and a 52-week high of $70.36. The company has a quick ratio of 1.84, a current ratio of 1.92 and a debt-to-equity ratio of 0.01. The firm has a market cap of $14.91 billion, a price-to-earnings ratio of 20.12, a PEG ratio of 5.30 and a beta of 0.73. The business’s 50 day moving average is $64.79 and its two-hundred day moving average is $60.94.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.78 by ($2.60). Incyte had a net margin of 2.52% and a return on equity of 0.75%. The firm had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $0.77 earnings per share. The business’s revenue was up 9.3% on a year-over-year basis. Analysts forecast that Incyte Co. will post 0.66 EPS for the current fiscal year.

Insider Activity at Incyte

In other Incyte news, insider Thomas Tray sold 572 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.94, for a total transaction of $36,001.68. Following the completion of the transaction, the insider now directly owns 24,825 shares of the company’s stock, valued at approximately $1,562,485.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Incyte news, EVP Jonathan Elliott Dickinson sold 8,450 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.36, for a total value of $526,942.00. Following the transaction, the executive vice president now owns 36,390 shares of the company’s stock, valued at approximately $2,269,280.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Thomas Tray sold 572 shares of Incyte stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $62.94, for a total value of $36,001.68. Following the completion of the transaction, the insider now owns 24,825 shares in the company, valued at $1,562,485.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 24,593 shares of company stock worth $1,652,914 in the last ninety days. 17.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

INCY has been the topic of several recent analyst reports. Citigroup increased their target price on Incyte from $80.00 to $88.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. Truist Financial reiterated a “hold” rating and set a $74.00 price objective (down from $83.00) on shares of Incyte in a report on Wednesday, September 18th. Wells Fargo & Company lowered their target price on shares of Incyte from $63.00 to $62.00 and set an “equal weight” rating for the company in a report on Thursday, October 10th. Wolfe Research started coverage on shares of Incyte in a research report on Tuesday, October 1st. They set an “outperform” rating and a $84.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Incyte from $55.00 to $60.00 and gave the company a “hold” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $73.21.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.